Visterra Finds Funding From Gates Foundation

Visterra, a biopharmaceuticals developer focusing on novel medicines to prevent and treat infections, said last week that it has raised $26M in a Series A round, led by the Bill and Melinda Gates Foundation. The funding also include Omega Funds, Polaris Venture Partners, Flagship Ventures and Lux Capital. Visterra said the funding will go to develop and validate its product pipeline. The firm's lead compound is a broad spectrum antibody for the prevention and treatment of both seasonal and pandemic influenza. More information »